Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- NA
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
- Status
- RECRUITING
- Phase
- NA
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
- Status
- RECRUITING
- Phase
- PHASE1
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
VAH vs VA in Newly Diagnosed Elderly AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
- Status
- RECRUITING
- Phase
- NA
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
FLT3-ITD Targeted Therapy in Fit AML Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3